HDAC9 and type 2 diabetes mellitus: In an attempt to rescue the Hdac7-associated beta cell dysfunction, and to test if HDAC7 may be a potential target for novel type 2 diabetes therapies, we treated Hdac7-overexpressing beta cells with two different HDAC inhibitors: TSA (an inhibitor of class I and class II HDACs) and MC1568 (an inhibitor of class II HDACs) [16, 17].